Update shared on27 Sep 2025
Fair value Decreased 3.79%China Vanke’s fair value estimate was revised down as its net profit margin deteriorated materially, despite a lower discount rate, resulting in a consensus price target cut from CN¥6.80 to CN¥6.54.
What's in the News
- China Vanke will hold a board meeting to consider and approve interim results for the six months ended June 30, 2025.
- The company issued negative earnings guidance for H1 2025, projecting a net loss attributable to shareholders of RMB 10,000 million to RMB 12,000 million, an increase in loss compared to the previous year.
- Losses are due to a significant decline in the settlement scale of real estate projects, persistently low gross profit margins, higher asset impairment provisions amid increased business risks, and asset or equity transactions below book value.
Valuation Changes
Summary of Valuation Changes for China Vanke
- The Consensus Analyst Price Target has fallen slightly from CN¥6.80 to CN¥6.54.
- The Discount Rate for China Vanke has significantly fallen from 13.13% to 10.08%.
- The Net Profit Margin for China Vanke has significantly fallen from 9.88% to 7.94%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.